Abstract
Purpose of Review
Acute postoperative pain reduction is a major target against the opioid crisis. While opioids have traditionally been the mainstay for postoperative analgesia, current practice has focused on a multimodal approach to pain control, including ultrasound-guided blocks with longer acting local anesthetic agents.
Recent Findings
Non-steroidal anti-inflammatory drugs (NSAIDs), such as meloxicam, are an important class of medications utilized to manage pain in the perioperative period. An additional treatment used in perioperative or postoperative pain relief is Exparel, a bupivacaine (sodium channel blocker) liposomal injectable suspension with a 3–4-day duration of action. The long-acting mechanism and formulation of Exparel consistently has demonstrated decreased opioid use and pain scores in patients undergoing many different surgical procedures. A concern is that pH negatively alters the efficacy of bupivacaine, as in cases of inflamed tissue and acidic fluid pH. For this reason, a combination medication with both meloxicam and bupivacaine has been developed, which normalizes pH and has anti-inflammatory and anti-pain conduction properties. Clinical studies demonstrate that this combination agent can be extremely beneficial in treating postoperative pain.
Summary
This manuscript summarizes the newest developments with regard to liposomal bupivacaine and the non-steroidal meloxicam, their roles in effective treatment of postoperative pain, contraindications, special considerations of using these medications, and future considerations. HTX-011 pairs up a new extended-release formulation of the local anesthetic bupivacaine with meloxicam, a well-established non-steroidal anti-inflammatory drug (NSAID).
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287–98.
Coley KC, Williams BA, DaPos SV, Chen C, Smith RB. Retrospective evaluation of unanticipated admissions and readmissions after same day surgery and associated costs. J Clin Anesth. 2002;14:349–53.
Simon LS. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. J Pain Palliat Care Pharmacother. 2012;26:197–8.
Wunsch H, Wijeysundera DN, Passarella MA, Neuman MD. Opioids prescribed after low-risk surgical procedures in the United States, 2004-2012. JAMA. 2016;315:1654.
•• American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248–73 Excellent task force report on practice guidelines for acute pain management from the American Society of Anesthesiologists.
Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002;29:436–46.
•• Bekker A, Kloepping C, Collingwood S. Meloxicam in the management of post-operative pain: narrative review. J Anaesthesiol Clin Pharmacol. 2018;34:450–7 Excellent review on meloxicam for post-operative pain.
Ahmed M, Khanna D, Furst DE. Meloxicam in rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2005;1:739–51.
Ang MJ, Silkiss RZ. The use of long-acting liposomal bupivacaine (Exparel) for postoperative pain control following enucleation or evisceration. Ophthal Plast Reconstr Surg. 2018;34:599.
Connor RS, Lenger SM, Kilgore LC, Kimball KJ. Liposomal bupivacaine (Exparel) for postoperative pain control following robotic hysterectomy [16E]. Obstet Gynecol. 2016;127:47S.
Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of Exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplast. 2014;30:325–9.
Jacob BC, Peasah SK, Shogbon AO, Perlow ER. Postoperative pain management with liposomal bupivacaine in patients undergoing orthopedic knee and hip arthroplasty at a community hospital. Hosp Pharm. 2017;52:367–73.
Becker DE, Reed KL. Essentials of local anesthetic pharmacology. Anesth Prog American Dental Society of Anesthesiology. 2006;53:98–108 quiz 109–10.
Noble S, Balfour JA. Meloxicam. Drugs. 1996;51:424–30.
Thompson JP, Sharpe P, Kiani S, Owen-Smith O. Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br J Anaesth. 2000;84:151–4.
Pollak RA, Gottlieb IJ, Hakakian F, Zimmerman JC, McCallum SW, Mack RJ, et al. Efficacy and safety of intravenous meloxicam in patients with moderate-to-severe pain following bunionectomy: a randomized, double-blind, placebo-controlled trial. Clin J Pain. 2018;34:918–26.
Stei P, Kruss B, Wiegleb J, Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br J Rheumatol. 1996;35(Suppl 1):44–50.
Xu S, Hermanson DJ, Banerjee S, Ghebreselasie K, Clayton GM, Garavito RM, et al. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding network. J Biol Chem. 2014;289:6799–808.
Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996;35(Suppl 1):13–6.
Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl 1):68–77.
Gottlieb IJ, Tunick DR, Mack RJ, McCallum SW, Howard CP, Freyer A, et al. Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy. J Pain Res. 2018;11:383–93.
Kurukahvecioglu O, Karamercan A, Ege B, Koksal H, Anadol Z, Tezel E, et al. Effect of meloxicam on postoperative pain relief after inguinal hernia repair with local anaesthesia. West Indian Med J. 2007;56:530–3.
Rømsing J, Mysager S, Vilmann P, Sonne J, Larsen NE, Stergaard D. Postoperative analgesia is not different after local vs systemic administration of meloxicam in patients undergoing inguinal hernia repair. Can J Anaesth 2001;48:978–984.
Aoki T, Yamaguchi H, Naito H, Shiiki K, Izawa K, Ota Y, et al. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006;35:613–7.
Orozco-Solis M, Garcia-Avalos Y, Pichardo-Ramirez C, Tobias-Azua F, Zapata-Morales J, Aragon-Martinez O, et al. Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016;21:e127–34.
Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012;28:1609–15.
FDA. EXPAREL® (bupivacaine liposome injectable suspension) Meeting of the Anesthetic and Analgesic Drug Products Advisory Commitee. Fda Advis Comm Meet Brief Doc. 2014;1–63.
FDA. FDA In Brief: FDA approves new use of Exparel for nerve block pain relief following shoulder surgeries. US Dep Heal Hum Serv. 2018;2018–9.
Lambrechts M, O’Brien MJ, Savoie FH, You Z. Liposomal extended-release bupivacaine for postsurgical analgesia. Patient Prefer Adherence. 2013;7:885–90.
Register S, About H, Kurtz S, Ong K, Lau E, Mowat F, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030 JBJS | Projections of Primary and Revision Hip and Knee Arthroplasty in t ... 2011;11–2.
Asche CV, Dagenais S, Kang A, Ren J, Maurer BT. Impact of treatment with liposomal bupivacaine on hospital costs, length of stay, and discharge status in patients undergoing total knee arthroplasty at high-use institutions. J Med Econ. 2019;22:85–94.
Lieblich SE, Danesi H. Liposomal bupivacaine use in third molar impaction surgery: INNOVATE study. Anesth Prog. 2017;64:127–35.
Prabhu M, Clapp MA, McQuaid-Hanson E, Ona S, O’Donnell T, James K, et al. Liposomal bupivacaine block at the time of cesarean delivery to decrease postoperative pain a randomized controlled trial. Obstet Gynecol. 2018;132:70–8.
Haas E, Onel E, Miller H, Ragupathi M, White PF. A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg. 2012;78(5):574–81.
Balocco AL, Van Zundert PGE, Gan SS, Gan TJ, Hadzic A. Extended release bupivacaine formulations for postoperative analgesia: an update. Curr Opin Anaesthesiol. 2018;31:636–42.
Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupivacaine in anesthesia practice. J Anaesthesiol Clin Pharmacol. 2017;33(2):151–6.
FDA. US Food and Drug Administration. FDA label approved on 10/28/2011 (PDF) for Exparel. US Silver Spring, MD: US Food and Drug Administration; [Accessed May 01, 2012]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf.
Fozzard HA, Sheets MF, Hanck DA. The sodium channel as a target for local anesthetic drugs. Front Pharmacol. 2011;2:68.
Cummings K III, Chahar P. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257–64.
Kessler ER. Response to “Bupivacaine Liposomal versus Bupivacaine: Comparative Review”. Hosp Pharm. 2014;49:793–5.
• Ilfeld BM, Viscusi ER, Hadzic A, Minkowitz HS, Morren MD, Lookabaugh J, et al. Safety and side effect profile of liposome bupivacaine (Exparel) in peripheral nerve blocks. Reg Anesth Pain Med. 2015;40:572–82 Safety and side effect profile of liposomal bupivicaine.
Bs THA, Liss FE, Ilyas AM. A prospective randomized study comparing bupivacaine hydrochloride versus bupivacaine liposome for pain management after distal radius fracture repair surgery. J Hand Surg [Am]. 2017;42:1003–8.
Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K, et al. Addition of liposome bupivacaine to bupivacaine HCl versus bupivacaine HCl alone for interscalene brachial plexus block in patients having major shoulder surgery. Reg Anesth Pain Med. 2017;42:334–41.
Kendall MC, Jorge L, Alves C, Jr GDO. Liposome bupivacaine compared to plain local anesthetics to reduce postsurgical pain : an updated meta-analysis of randomized controlled trials. Hindawi. 2018;2018.
EXPAREL. Parsippany, NJ: Pacira Pharmaceuticals, Inc; 2019. Available from https://www.exparel.com/sites/default/files/PP-EX-US-3647_EXPAREL_Fast_Facts_Update.pdf.
Ilfeld BM. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. Expert Opin Pharmacother. 2013;14:2421–31.
Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54:1552–9.
Skolnik A, Gan TJ. New formulations of bupivacaine for the treatment of postoperative pain: liposomal bupivacaine and SABER-Bupivacaine. Expert Opin Pharmacother. 2014;15:1535–42.
Balocco AL, Van Zundert PGE, Gan SS, Gan TJ, Hadzic A. Extended release bupivacaine formulations for postoperative analgesia. Curr Opin Anaesthesiol. 2018;31:1.
P. Winkle, H.S. Minkowitz, E. Onel, G. Boccia, A. Chu, N.J. Clendeninn, M.R. Keller, T. Ottoboni, S.S. Patel BQ. Heron hernia clinical trial results. http://www.herontx.com/sites/default/files/pdfs/posters-presentations/Heron_PainWeek_2016_Hernia_Results_L2c_091516.pdf. 2016;
Heron Therapeutics. Evaluation of the efficacy and safety of HTX-011 for postoperative analgesia following abdominoplasty surgery. ClinicalTrials.gov.
Heron Therapeutics. Evaluation of the efficacy and safety of locally administered HTX-011 for postoperative analgesia following bunionectomy - full text view - ClinicalTrials.gov. ClinicalTrials.gov.
Heron Therapeutics. A pilot study to investigate the safety, efficacy, pharmacokinetics and bioavailability of HTX-011, HTX-002, or HTX-009 administered via injection and/or topical application following unilateral open inguinal herniorrhaphy. ClinicalTrials.gov. 2015.
Heron Therapeutics. Heron announces positive topline results from pivotal phase 3 clinical trials of HTX-011 in bunionectomy and hernia repair.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Matthew Notitch, Sam Carlson, Mitchell Fuller, Shane White, Mohamed Elkersh, Alexander Haroldson, Jennifer Kaiser, Andrew Brunk, George Jeha, and Elyse Cornett declare no conflict of interest.
Alan Kaye is a Section Editor for Current Headache and Pain Reports. He has not been involved in the editorial handling of this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Other Pain
Rights and permissions
About this article
Cite this article
Kaye, A.D., Novitch, M.B., Carlson, S.F. et al. The Role of Exparel Plus Meloxicam for Postoperative Pain Management. Curr Pain Headache Rep 24, 6 (2020). https://doi.org/10.1007/s11916-020-0837-2
Published:
DOI: https://doi.org/10.1007/s11916-020-0837-2